Results 131 to 140 of about 23,280 (257)

Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDiminished growth hormone (GH) is associated with impaired endothelial function and fibrinolysis. GH‐releasing hormone is the primary stimulus for GH secretion and a substrate of dipeptidyl peptidase‐4.
Jessica R. Wilson, Nancy J. Brown, Hui Nian, Chang Yu, Martin Bidlingmaier, Jessica K. Devin   +5 more
doaj   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

, 2015
Seitaro Omoto,1 Takehito Taniura,2 Tohru Nishizawa,3 Takeshi Tamaki,3 Akira Shouzu,4 Shosaku Nomura3 1Division of Internal Medicine, Korigaoka Yukeikai Hospital, 2Division of Internal Medicine, Daiwa Hospital, 3First Department of Internal Medicine ...
Omoto S, Taniura T, Tamaki T, Shouzu A,Nomura S, Nishizawa T   +4 more
core  

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction

, 2016
Muhammad Waqas Khan,1 Saji Kurian,2 Rohit Bishnoi1 1Division of Hospital Medicine, Department of Medicine, College of Medicine, 2College of Pharmacy, University of Florida, Gainesville, FL, USA Abstract: Rhabdomyolysis is a serious medical condition in ...
Khan MW, Bishnoi R, Kurian S
core  

Pancreatic Safety of Sitagliptin in the TECOS Study. [PDF]

, 2016
Objective We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).
Josse, Robert, Lachin, John M, Peterson, Eric D, Tankova, T, Lachin, John M., Peterson, Eric D., Grado, Carlos R., Holman, RR, Engel, Samuel S, Engel, SS, Stevens, Susanna R, TECOS Study Group, Bethel, M Angelyn, Patel, Keyur, Buse, John B., Wainstein, Julio, Buse, JB, Tankova, Tsvetalina, Buse, John B, Lokhnygina, Yuliya, Bethel, MA, Bethel, M. Angelyn, Green, JB, Stevens, SR, Aschner, P, Patel, K, Engel, Samuel S., Aschner, Pablo, Holman, Rury R., Wainstein, J, Holman, Rury R, Green, Jennifer B., Stevens, Susanna R., Green, Jennifer B, Lachin, JM, Josse, R, Grado, CR, Grado, Carlos Raffo, Lokhnygina, Y, Peterson, ED   +39 more
core   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

, 2007
Baptist GallwitzDept. Medicine IV, Eberhard Karls University, Tuebingen, GermanyAbstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 ...
Baptist Gallwitz
core